Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Renal Transplantation Medication

  • Author: Bradley H Collins, MD; Chief Editor: Ron Shapiro, MD  more...
 
Updated: Oct 01, 2015
 

Medication Summary

The goals of pharmacotherapy are to prevent graft rejection, reduce morbidity, and prevent complications. Immunosuppression is often started prior to or during surgery. Transplant recipients are maintained on an immunosuppression regimen that includes 1-3 drugs. Immunosuppressant drug classes include calcineurin inhibitors, corticosteroids, antimetabolites, mTor inhibitors, and other immunosuppressants. Several regimens can be used, including pretransplantation induction therapy and simple postoperative maintenance therapy; the choice of regimen depends on the training and experience of the transplantation center. For additional information, see the Medscape topic Immunosuppression.

Next

Calcineurin Inhibitors

Class Summary

These agents induce immunosuppression by inhibiting the first phase of T-cell activation by binding to immunophilins (eg, cyclophilin, FK binding proteins) to form complexes that then bind to and inhibit the activated calcineurin phosphatase . Calcineurin is essential for the dephosphorylation of the nuclear factor of activation of T cells (NFAT) that activates T-cells. The first phase of T-cell activation causes transcriptional activation of interleukin (IL)-2, IL-3, IL-4, tumor necrosis factor (TNF) alpha, and interferon gamma that allow T-cells to progress from the G0- to G1-phase.

Tacrolimus (Prograf, Astagraf XL, Hecoria, Envarsus XR)

 

Tacrolimus is a calcineurin inhibitor with 2-3 times the potency of cyclosporine. Tacrolimus can be used at lower doses than cyclosporine, but its adverse effects include renal dysfunction, neurotoxicity (tremor, insomnia, and paresthesias of the extremities), and new-onset diabetes. Levels are adjusted according to renal function, hepatic function, and adverse effects. Tacrolimus has essentially replaced cyclosporine as the calcineurin inhibitor of choice, because of less rejection, less steroid-resistant rejection, more salvage after conversion from cyclosporine because of rejection, and in some studies, superior graft survival. Currently, 80-90% of patients receive tacrolimus after renal transplantation instead of cyclosporine, and this change has persisted over the past 10-15 years. Astagraf and Envarsus are once-daily formulations of tacrolimus. A number of generic formulations of the original tacrolimus are available.

Cyclosporine (Neoral, Sandimmune, Gengraf)

 

Cyclosporine is a cyclic polypeptide that suppresses some humoral immunity and, to a greater extent, cell-mediated immune reactions such as delayed hypersensitivity, allograft rejection, experimental allergic encephalomyelitis, and graft versus host disease for various organs.

For children and adults, base dosing on ideal body weight. Maintaining appropriate levels of the drug in the bloodstream is crucial to the maintenance of the allograft. Foods and time of administration can alter the level of the drug. Medication must be taken at the same time every day.

Neoral is the capsular form of the newer formulation of cyclosporine, available in 25- and 100-mg capsules. Sandimmune is the liquid form of the original formulation. Genraf is the branded generic form of the newer formulation, available in 25- and 100-mg capsules. There are many generic formulations of both the original and modified formulations.

Previous
Next

Corticosteroids

Class Summary

At pharmacologic doses, glucocorticoids suppress immune responses.

Prednisone (Deltasone)

 

Prednisone is an immunosuppressant used for the prevention or treatment of rejection. It may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear (PMN) leukocyte activity. It is an oral steroid with approximately 4 times the potency of endogenous steroids. All patients receive steroids around the time of the transplant; perhaps one third have steroids withdrawn within a few days of the transplant (steroid near-avoidance), and perhaps 10% have steroids withdrawn at a subsequent date. In spite of the numerous side effects, most transplant patients are maintained on long-term low-dose steroids.

Prednisolone (Orapred, Pediapred, Millipred)

 

Corticosteroids act as potent inhibitors of inflammation. They may cause profound and varied metabolic effects, particularly in relation to salt, water, and glucose tolerance, in addition to their modification of the immune response of the body.  Prednisolone is very similar to prednisone.

Methylprednisolone (Medrol, Solu-Medrol)

 

Methylprednisolone is an immunosuppressant used to prevent or treat rejection. It may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. It is the intravenous (IV) form of prednisone.

Previous
Next

Antimetabolites

Class Summary

Used for maintenance therapy in conjunction with a calcineurin inhibitor and prednisone.

Mycophenolate mofetil (CellCept, Myfortic)

 

Mycophenolate inhibits inosine monophosphate dehydrogenase (IMPDH) and suppresses de novo purine synthesis by lymphocytes, thus inhibiting their proliferation. It inhibits antibody production. It is the most prescribed immunosuppressive agent in transplantation. Two forms exist, mycophenolate mofetil (MMF, CellCept) a prodrug for mycophenolic acid (MPA, Myfortic). These agents are used in regimens containing a calcineurin inhibitor and corticosteroids for prevention of renal allograft rejection. There are many generic formulations.

Azathioprine (Imuran, Azasan)

 

Azathioprine antagonizes purine metabolism and inhibits synthesis of DNA, RNA, and proteins. It may decrease proliferation of immune cells, which results in lower autoimmune activity. Antimetabolites are used to block the uptake of vital nutrients needed by the cells. As implied, these drugs affect not only the cells of the immune system but also other cells of the body. The potency of therapy is dose-dependent. Azathioprine is not effective treatment for acute rejection episodes but remains an economical choice for long-term immunosuppression.  It was supplanted very quickly by mycophenolate mofetil when the latter became available.

Previous
Next

mTor Inhibitors

Class Summary

Inhibit T-cell activation and proliferation. Unlike calcineurin inhibitors, sirolimus and everolimus inhibit the second phase of T-cell activation. The second phase involves signal transduction and clonal proliferation of T-cells. These agents inhibit interleukin-induced proliferation of T-cells resulting in cell cycle arrest in hte late G1-phase and prevents progression to the S-phase. Sirolimus inhibits interleukin (IL)-2, IL-4, IL-7, IL-15, and IL-17. Everolimus inhibits IL-2 and IL-15.

Sirolimus (Rapamune)

 

Sirolimus, known in the past as rapamycin, is a macrocyclic lactone produced by Streptomyces hygroscopicus. It is a fairly potent immunosuppressant that inhibits T-cell activation and proliferation by a mechanism that is unknown but distinct from that used by all other immunosuppressants. This inhibition suppresses cytokine-driven T-cell proliferation by inhibiting progression from the G1 phase to the S phase in the cell cycle.  It is used in a minority of transplant recipients.

Everolimus (Zortress)

 

Everolimus is indicated for prophylaxis of organ rejection in patients with low to moderate immunologic risk following kidney transplantation. It is used in combination with reduced-dose cyclosporine, as well as basiliximab and corticosteroids. It inhibits the second phase of T-cell activation.

Previous
Next

Other Immunosuppressants

Class Summary

These agents may be used in various immunosuppressant regimens.

Belatacept (Nulojix)

 

Belatacept is a monoclonal antibody that inhibits T-cell CD28 activation and proliferation by binding costimulatory ligands (CD80, CD86) of antigen presenting cells. It is indicated for use in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids to prevent kidney transplant rejection.

Basiliximab (Simulect)

 

Interleukin-2 receptor antagonist indicated for prophylaxis of kidney transplant rejection. It is used as part of a regimen that includes a calcineurin inhibitor and corticosteroids. More recently, it has been used as part of induction regimens.

Antithymocyte globulin rabbit (ATG rabbit, Thymoglobulin)

 

Acts against human T-cell surface antigens and depletes CD4 lymphocytes. It is indicated for treatment of renal transplant acute rejection in conjunction with concomitant immunosuppression. It is also widely used off-label for induction. 

Alemtuzumab

 

Alemtuzumab is a humanized recombinant monoclonal antibody against CD52 that is approved by the FDA for chronic lymphocytic leukemia and multiple sclerosis. It is used off-label as part of various induction regimens in patients undergoing kidney transplantation. In numerous phase 3 clinical trials, alemtuzumab has demonstrated steroid-sparing effects, including improved glycemic stability. Leukopenia and neutropenia were reported. Careful patient selection is required. Long-term follow-up results from the 3C trial (NCT01120028) is pending regarding alemtuzumab’s role in reducing calcineurin inhibitor exposure by using a more potent induction regimen.

Previous
 
Contributor Information and Disclosures
Author

Bradley H Collins, MD Associate Professor, Department of Surgery, Division of Transplantation, Surgical Director of Kidney Transplantation, Surgical Director of Pancreas Transplantation, OPTN/UNOS Program Director of Kidney Transplantation and Pancreas Transplantation, Duke University Medical Center

Bradley H Collins, MD is a member of the following medical societies: American College of Surgeons, American Society of Transplant Surgeons, Society of University Surgeons

Disclosure: Nothing to disclose.

Chief Editor

Ron Shapiro, MD Professor of Surgery, Robert J Corry Chair in Transplantation Surgery, Associate Clinical Director, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center

Ron Shapiro, MD is a member of the following medical societies: American Society of Transplantation, American Surgical Association, American College of Surgeons, Transplantation Society, International Pediatric Transplant Association, American Society of Transplant Surgeons, Association for Academic Surgery, Central Surgical Association, Society of University Surgeons

Disclosure: Nothing to disclose.

Acknowledgements

Thomas D Johnston, MD Director, Renal and Pediatric Transplantation, Associate Professor, Department of Surgery, University of Kentucky

Thomas D Johnston, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Society of Transplant Surgeons, Association for Academic Surgery, International College of Surgeons US Section, and Kentucky Medical Association

Disclosure: Nothing to disclose.

Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association, Sexual Medicine Society of North America, and Tennessee Medical Association

Disclosure: Lilly Consulting fee Advisor; Astellas Consulting fee Speaking and teaching; Watson Consulting fee Speaking and teaching; Allergan Consulting fee Speaking and teaching

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. United Network for Organ Sharing (UNOS). Data. UNOS. Available at http://www.unos.org/donation/index.php?topic=data. August 28, 2015; Accessed: September 3, 2015.

  2. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, et al. OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant. 2014 Jan. 14 Suppl 1:11-44. [Medline]. [Full Text].

  3. Bartlett ST, Farney AC, Jarrell BE, et al. Kidney transplantation at the University of Maryland. Clin Transpl. 1998. 177-85. [Medline].

  4. Frassetto LA, Tan-Tam C, Stock PG. Renal transplantation in patients with HIV. Nat Rev Nephrol. 2009 Oct. 5(10):582-9. [Medline].

  5. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipient. Ther Drug Monit. 2000 Feb. 22(1):20-6. [Medline].

  6. Gallagher M, Jardine M, Perkovic V, Cass A, McDonald S, Petrie J, et al. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation. 2009 Jun 27. 87(12):1877-83. [Medline].

  7. Kahan BD, Julian BA, Pescovitz MD, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation. 1999 Nov 27. 68(10):1526-32. [Medline].

  8. Yakupoglu YK, Kahan BD. Sirolimus: a current perspective. Exp Clin Transplant. 2003 Jun. 1(1):8-18. [Medline].

  9. Oberholzer J, John E, Lumpaopong A, et al. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant. 2005 Aug. 9(4):456-63. [Medline].

  10. Kramer BK, Krager B, Mack M, et al. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens. Transplant Proc. 2005 May. 37(4):1789-91. [Medline].

  11. Berney T, Malaise J, Mourad M, et al. Laparoscopic and open live donor nephrectomy: a cost/benefit study. Transpl Int. 2000. 13(1):35-40. [Medline].

  12. Ratner LE, Montgomery RA, Kavoussi LR. Laparoscopic live donor nephrectomy: the four year Johns Hopkins University experience. Nephrol Dial Transplant. 1999 Sep. 14(9):2090-3. [Medline].

  13. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Stewart DE, et al. OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant. 2015 Jan. 15 Suppl 2:1-34. [Medline].

  14. Magee CC. Transplantation across previously incompatible immunological barriers. Transpl Int. Jan 2006. 19:87-97. [Medline]. [Full Text].

  15. Huh KH, Kim MS, Ju MK, Chang HK, Ahn HJ, Lee SH, et al. Exchange living-donor kidney transplantation: merits and limitations. Transpl. Aug 2008. 86:430-435. [Medline].

  16. Slagt I, Klop K, Ijzermans J. Intravesical versus extravesical ureteroneocystostomy in kidney transplantation: A systematic review and meta-analysis. Transplantation. October 2012.

  17. Isoniemi H, Lehtonen S, Salmela K, Ahonen J. Does delayed kidney graft function increase the risk of chronic rejection?. Transpl Int. 1996. 9 Suppl 1:S5-7. [Medline].

  18. Johnston TD, Thacker LR, Jeon H, et al. Sensitivity of expanded-criteria donor kidneys to cold ischaemia time. Clin Transplant. 2004. 18 Suppl 12:28-32. [Medline].

  19. al-Aasfari R, Hadidy S, Yagan S. Infectious complications of kidney transplantation. Transplant Proc. 1999 Dec. 31(8):3204. [Medline].

  20. Varon NF, Alangaden GJ. Emerging trends in infections among renal transplant recipients. Expert Rev Anti Infect Ther. 2004 Feb. 2(1):95-109. [Medline].

  21. Adamska Z, Karczewski M, Cichańska L, Więckowska B, Małkiewicz T, Mahadea D, et al. Bacterial Infections in Renal Transplant Recipients. Transplant Proc. 2015 Jul-Aug. 47 (6):1808-12. [Medline].

 
Previous
Next
 
End-to-side anastomosis between donor main renal artery just above its bifurcation and recipient external iliac artery.
Laparoscopic donor nephrectomy.
Table 1. Demographics of adult patients on the waiting list for kidney transplants, United States, 2012 [2]
Patient Characteristic Number of Patients Percentage
Age 18-34 y 8811 9.5
Age 35-49 y 24,799 26.7
Age 50-64 y 40,523 43.6
Age 65-74 y 16,779 18.1
Age >75 y 1973 2.1
Male 55,104 59.3
Female 37,781 40.7
White 35,189 37.9
Black 31,607 34.0
Hispanic 17,536 18.9
Asian 7218 7.8
Table 2. Primary causes of ESRD in adult patients on the kidney transplant waiting list: United States, 2012 [2]
Cause of ESRD Number of Patients Percentage
Diabetes 31,801 34.2
Hypertension 23,209 25.0
Glomerulonephritis 13,068 14.1
Cystic kidney 7591 8.2
Other or unknown cause 17 18.5
ESRD = End-stage renal disease    
Table 3. Demographics of pediatric patients awaiting kidney transplant: United States, 2012 [2]
Patient Characteristic Percentage
Age <1 y 1.0
Age 1-5 y 15.9
Age 6-10 y 14.1
Age 11-17 y 69.0
White 40.8
Black 25.4
Hispanic 28.6
Asian 3.5
Other or unknown 1.8
Table 4. Primary causes of end-stage renal disease in pediatric patients on the kidney transplant waiting list: United States, 2012 [2]
Cause of Renal Failure Percentage
Focal segmental glomerulosclerosis 12.0
Glomerulonephritis 10.8
Structural 26.9
Other or unknown 50.3
ESRD = End-stage renal disease  
Table 5. Five-year post-transplant survival with a functioning kidney graft: United States, 2012
Patient Characteristics Percentage
Age <11 y, deceased donor 75
Age <11 y, living donor 89
Age 11-17 y, deceased donor 67
Age 11-17, live donor 77
Adults, deceased donor 73
Adults, living donor 84
Adults transplanted for diabetes 71
Adults transplanted for hypertension 70
Adults transplanted for glomerulonephritis 77
Adults transplanted for cystic kidney disease 82
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.